These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

907 related articles for article (PubMed ID: 30170567)

  • 1. Assessing the sensitivity of placental growth factor and soluble fms-like tyrosine kinase 1 at 36 weeks' gestation to predict small-for-gestational-age infants or late-onset preeclampsia: a prospective nested case-control study.
    MacDonald TM; Tran C; Kaitu'u-Lino TJ; Brennecke SP; Hiscock RJ; Hui L; Dane KM; Middleton AL; Cannon P; Walker SP; Tong S
    BMC Pregnancy Childbirth; 2018 Aug; 18(1):354. PubMed ID: 30170567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble fms-like tyrosine kinase to placental growth factor ratio in different stages of early-onset fetal growth restriction and small for gestational age.
    Garcia-Manau P; Mendoza M; Bonacina E; Garrido-Gimenez C; Fernandez-Oliva A; Zanini J; Catalan M; Tur H; Serrano B; Carreras E
    Acta Obstet Gynecol Scand; 2021 Jan; 100(1):119-128. PubMed ID: 32860218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Placental growth factor and soluble fms-like tyrosine kinase-1 are useful markers for the prediction of preeclampsia but not for small for gestational age neonates: a longitudinal study.
    Rizos D; Eleftheriades M; Karampas G; Rizou M; Haliassos A; Hassiakos D; Vitoratos N
    Eur J Obstet Gynecol Reprod Biol; 2013 Dec; 171(2):225-30. PubMed ID: 24035323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of small-for-gestational-age neonates: screening by placental growth factor and soluble fms-like tyrosine kinase-1 at 35-37 weeks.
    Fadigas C; Peeva G; Mendez O; Poon LC; Nicolaides KH
    Ultrasound Obstet Gynecol; 2015 Aug; 46(2):191-7. PubMed ID: 25825848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of small-for-gestational-age neonates: screening by biophysical and biochemical markers at 30-34 weeks.
    Bakalis S; Peeva G; Gonzalez R; Poon LC; Nicolaides KH
    Ultrasound Obstet Gynecol; 2015 Oct; 46(4):446-51. PubMed ID: 25826154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of small for gestational age neonates: screening by maternal factors, fetal biometry, and biomarkers at 35-37 weeks' gestation.
    Ciobanu A; Rouvali A; Syngelaki A; Akolekar R; Nicolaides KH
    Am J Obstet Gynecol; 2019 May; 220(5):486.e1-486.e11. PubMed ID: 30707967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarkers of impaired placentation at 35-37 weeks' gestation in the prediction of adverse perinatal outcome.
    Ciobanou A; Jabak S; De Castro H; Frei L; Akolekar R; Nicolaides KH
    Ultrasound Obstet Gynecol; 2019 Jul; 54(1):79-86. PubMed ID: 31100188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biophysical and biochemical markers at 30-34 weeks' gestation in the prediction of adverse perinatal outcome.
    Valiño N; Giunta G; Gallo DM; Akolekar R; Nicolaides KH
    Ultrasound Obstet Gynecol; 2016 Feb; 47(2):194-202. PubMed ID: 26094952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiogenic factors in maternal circulation and preeclampsia with or without fetal growth restriction.
    Vatten LJ; Åsvold BO; Eskild A
    Acta Obstet Gynecol Scand; 2012 Dec; 91(12):1388-94. PubMed ID: 22882089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maternal serum biomarkers of placental insufficiency at 24-28 weeks of pregnancy in relation to the risk of delivering small-for-gestational-age infant in Sylhet, Bangladesh: a prospective cohort study.
    Rahman S; Islam MS; Roy AK; Hasan T; Chowdhury NH; Ahmed S; Raqib R; Baqui AH; Khanam R
    BMC Pregnancy Childbirth; 2024 Jun; 24(1):418. PubMed ID: 38858611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of small-for-gestational-age neonates: screening by maternal biochemical markers at 30-34 weeks.
    Bakalis S; Gallo DM; Mendez O; Poon LC; Nicolaides KH
    Ultrasound Obstet Gynecol; 2015 Aug; 46(2):208-15. PubMed ID: 25826797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum placental growth factor and soluble fms-like tyrosine kinase 1 at mid-gestation in healthy women: Association with small-for-gestational-age neonates.
    Furuta I; Umazume T; Kojima T; Chiba K; Nakagawa K; Hosokawa A; Ishikawa S; Yamada T; Morikawa M; Minakami H
    J Obstet Gynaecol Res; 2017 Jul; 43(7):1152-1158. PubMed ID: 28422347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Value of second trimester maternal serum sFlt-1, PlGF and their ratio in the prediction of preeclampsia].
    Gao J; Shen J; Jiang Y; Zhou X; Qi H; Liu X; Liu J; Yang J; Bian X
    Zhonghua Fu Chan Ke Za Zhi; 2014 Jan; 49(1):22-5. PubMed ID: 24694913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of sFlt-1/PlGF ratio and feto-maternal Doppler for the prediction of adverse perinatal outcome in late-onset pre-eclampsia.
    Graupner O; Karge A; Flechsenhar S; Seiler A; Haller B; Ortiz JU; Lobmaier SM; Axt-Fliedner R; Enzensberger C; Abel K; Kuschel B
    Arch Gynecol Obstet; 2020 Feb; 301(2):375-385. PubMed ID: 31734756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of pre-eclampsia within 4 weeks of sFlt-1/PlGF ratio > 38: comparison of performance at 31-34 vs 35-37 weeks' gestation.
    Dragan I; Wright D; Fiolna M; Leipold G; Nicolaides KH
    Ultrasound Obstet Gynecol; 2017 Feb; 49(2):209-212. PubMed ID: 27671743
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Soluble fms-like tyrosine kinase 1 is increased in preeclampsia but not in normotensive pregnancies with small-for-gestational-age neonates: relationship to circulating placental growth factor.
    Shibata E; Rajakumar A; Powers RW; Larkin RW; Gilmour C; Bodnar LM; Crombleholme WR; Ness RB; Roberts JM; Hubel CA
    J Clin Endocrinol Metab; 2005 Aug; 90(8):4895-903. PubMed ID: 15886253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of competing-risks model with angiogenic factors in midgestation screening for preterm growth-related neonatal morbidity.
    Papastefanou I; Menenez M; Szczepkowska A; Gungil B; Syngelaki A; Nicolaides KH
    Ultrasound Obstet Gynecol; 2024 May; 63(5):613-618. PubMed ID: 38057964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia.
    Chaiworapongsa T; Romero R; Korzeniewski SJ; Kusanovic JP; Soto E; Lam J; Dong Z; Than NG; Yeo L; Hernandez-Andrade E; Conde-Agudelo A; Hassan SS
    Am J Obstet Gynecol; 2013 Apr; 208(4):287.e1-287.e15. PubMed ID: 23333542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma soluble fms-like tyrosine kinase 1 to placental growth factor ratio of 11.5 multiples of median predicts preeclampsia with severe features within 2 weeks of testing.
    Espinoza J; Calsavara VF; Kilpatrick S; Rana S; Costantine MM; Boggess K; Wylie BJ; Moore Simas TA; Louis JM; Gaw SL; Murtha A; Wiegand S; Gollin Y; Singh D; Silver RM; Durie DE; Panda B; Norwitz ER; Burd I; Plunkett B; Scott RK; Lemoine E; Thadhani R; Karumanchi SA
    Am J Obstet Gynecol; 2024 Sep; 231(3):363.e1-363.e11. PubMed ID: 38825028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble Fms-like tyrosine kinase-1 to placental growth factor ratio in mid-pregnancy as a predictor of preterm preeclampsia in asymptomatic pregnant women.
    Forest JC; Thériault S; Massé J; Bujold E; Giguère Y
    Clin Chem Lab Med; 2014 Aug; 52(8):1169-78. PubMed ID: 24535301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.